Haematological malignancies research hub

A Phase I/IIa trial of NVG-222 in blood cancers

This trial tests a new drug, NVG-222, for blood cancers. It aims to find the safest dose, understand side effects, and see if it can shrink or control cancer by helping the body's immune system fight cancer cells. It's for adults whose cancer has returned or is not responding to other treatments.